Watchlist Price Alert

Sutro Biopharma Inc. (STRO)

NASDAQ: STRO · Real-Time Price · USD

0.83

-0.08 (-8.73%)

At close: Jun 05, 2025, 3:59 PM

0.81

-2.16%

After-hours: Jun 05, 2025, 07:57 PM EDT

-8.73% (1D)

Bid	0.7
Market Cap	69.93M
Revenue (ttm)	66.43M
Net Income (ttm)	-245.22M
EPS (ttm)	-2.92
PE Ratio (ttm)	-0.28
Forward PE	-0.91
Analyst	Hold

Ask	0.98
Volume	1,365,785
Avg. Volume (20D)	1,876,692
Open	0.92
Previous Close	0.91
Day's Range	0.82 - 0.92
52-Week Range	0.52 - 5.17
Beta	1.71

About STRO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol STRO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for STRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-35.19%

Sutro Biopharma shares are trading lower after B o... Unlock content with Pro Subscription

6 months ago

-12.88%

Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q3 sales results.

News

4 weeks ago · zacks.com

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.

2 months ago · benzinga.com

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.

2 months ago · zacks.com

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.